Decrease in linoleic acid metabolites as a potential mechanism in cancer risk reduction by conjugated linoleic acid

Decrease in linoleic acid metabolites as a potential mechanism in cancer risk reduction by conjugated linoleic acid.

Previous research suggested that conjugated linoleic acid (CLA) feeding during the period of pubescent mammary gland development in the rat resulted in diminished mammary epithelial branching which might account for the reduction in mammary cancer risk. Terminal end buds (TEB) are the primary sites for the chemical induction of mammary carcinomas in rodents. One of the objectives of the present...

Conjugated Linoleic Acid Targets

Conjugated Linoleic Acid

Conjugated linoleic acid, better known as CLA, is a fatty acid derived from the required nutrient, linoleic acid. The major structural difference between linoleic acid (an 18 carbon, polyunsaturated fatty acid) and CLA, is that linoleic acid has double bonds at carbons 9 and 12 in a cis configuration (methylene interrupted), while CLA has numerous isomers without methylene interrupted conjugate...

Conjugated linoleic acid: a review.

Conjugated linoleic acid (CLA) refers to a group of positional and geometric isomers of the omega-6 essential fatty acid linoleic acid (cis-9, cis-12, octadecadienoic acid). In humans evidence is currently ambiguous as to whether CLA supplementation has a significant effect on body composition. Despite favorable changes in lipid levels in animal models, a beneficial effect in humans has not yet...

Conjugated linoleic acid isomers and cancer.

We reviewed the literature regarding the effects of conjugated linoleic acid (CLA) preparations enriched in specific isomers, cis9, trans11-CLA (c9, t11-CLA) or trans10, cis12-CLA (t10, c12-CLA), on tumorigenesis in vivo and growth of tumor cell lines in vitro. We also examined the potential mechanisms by which CLA isomers may alter the incidence of cancer. We found no published reports that ex...